Evidence map›Paper›PMID 42338041›Full record

ArticleSmall methods2026

Immune-Evasive Biomimetic Gold-Carbon Nanoplatform for Dual-Modal Theranostics of Hepatocellular Carcinoma.

Pengcheng Pan, Xinyi Hou, Yan Wang, Huan Lin, Xiangkun Miao, Yuanyuan Wang, Yuxiang Gao, Chenyu Hu, Pir Muhammad, Lifang Gao and 3 more

Abstract read
In one paragraph

Article in Small methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Pengcheng PanInternational Joint Research Center of Human-machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, College of Pharmacy, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, Hainan, China.
Xinyi HouInternational Joint Research Center of Human-machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, College of Pharmacy, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, Hainan, China.
Yan WangInternational Joint Research Center of Human-machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, College of Pharmacy, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, Hainan, China.
Huan LinInternational Joint Research Center of Human-machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, College of Pharmacy, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, Hainan, China.
Xiangkun MiaoInternational Joint Research Center of Human-machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, College of Pharmacy, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, Hainan, China.
Yuanyuan WangInternational Joint Research Center of Human-machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, College of Pharmacy, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, Hainan, China.
Yuxiang GaoInternational Joint Research Center of Human-machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, College of Pharmacy, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, Hainan, China.
Chenyu HuInternational Joint Research Center of Human-machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, College of Pharmacy, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, Hainan, China.
Pir MuhammadInternational Joint Research Center of Human-machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, College of Pharmacy, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, Hainan, China.ORCID https://orcid.org/0000-0001-5960-0279
Lifang GaoInternational Joint Research Center of Human-machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, College of Pharmacy, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, Hainan, China.
Junfeng ZhangSchool of Medicine, Anhui University of Science and Technology, Huainan, China.ORCID https://orcid.org/0009-0004-7518-1771
Chenchen LiInternational Joint Research Center of Human-machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, College of Pharmacy, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, Hainan, China.
Yanli WangInternational Joint Research Center of Human-machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, College of Pharmacy, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, Hainan, China.

Funding

Anhui Provincial Natural Science Foundation 2508085QH330Education Department of Hainan Province Hnky2025-22Innovative Research Project for Graduate Students of Hainan Medical University HYYB2023A03'Nanhai Xinxing' Science and Technology Innovation Talent Platform Project of Hainan Province NHXXRCXM202318National Natural Science Foundation of China 52371250National Natural Science Foundation of China 82325030National Natural Science Foundation of China 82502551National Natural Science Foundation of China 82502552Science and Technology special fund of Hainan Province ZDYF2024SHFZ080
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) remains refractory to systemic therapy due to poor tumor selectivity, rapid drug clearance, and acquired resistance to sorafenib (SF). Here, we report a membrane-engineered biomimetic gold-carbon theranostic nanoplatform (ARG-SF@M) that integrates immune evasion, homologous targeting, dual-modal imaging, and synergistic chemo-photothermal therapy (chemo-PTT) within a single nanosystem. The platform is constructed by co-assembling gold nanorods (AuNRs) and a fluorescent carbon nanomaterial (GTTN) for efficient SF loading, followed by cloaking with HCC cell membranes to confer prolonged circulation and tumor-homotypic recognition. AuNRs enable efficient near-infrared photothermal conversion and thermal imaging (TI), while GTTN provides stable fluorescence imaging (FI) for real-time biodistribution monitoring. The membrane camouflage markedly enhances tumor accumulation and reduces off-target distribution, thereby improving SF delivery efficiency. In vivo studies demonstrate that ARG-SF@M achieves a tumor inhibition rate of 81.92%, significantly higher than that of free SF (42.43%) and non-biomimetic ARG-SF (66.05%). Under NIR irradiation, tumor suppression further increases to 90.77%, substantially outperforming AuNRs + L (55.35%), confirming strong chemo-PTT synergy. Mechanistically, photothermal activation induces intratumoral hyperthermia, mitochondrial dysfunction, excessive reactive oxygen species generation, HSP70 upregulation, and activation of the mitochondrial apoptotic pathway. Collectively, this work presents a rational biomimetic membrane-engineering strategy for imaging-guided precision HCC theranostics.

Indexed as

Biomimetic MaterialsCarcinoma, HepatocellularGoldLiver NeoplasmsTheranostic NanomedicineAnimalsAntineoplastic AgentsBiomimeticsCarbonCarbon NanomaterialsCell Line, TumorHumansMiceMice, Inbred BALB CMice, NudePhotothermal TherapyAntineoplastic AgentsCarbonGoldSorafenibbiocompatibilitybiomimetic membrane‐engineereddual‐modal theragnostichomologous targetedimmune‐Evasive

Identifiers

PMID42338041
PMCPMC13397195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.